GNE-9605 is a highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor [1]. The compound is able to cross the blood-brain barrier identifying it as a potential lead in developing a novel disease-modifying Parkinson’s disease therapy.